There are currently 83 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
Recruiting
The body has different ways of fighting infection and disease. No single way is perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Recruiting
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: City of Hope Medical Center, Duarte, California +5 locations
Conditions: COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Sample Collection and Tracking for the Developmental Therapeutics Clinic
Recruiting
Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Lymphoma
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Recruiting
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
Recruiting
The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn if inotuzumab ozogamicin when given after a stem cell transplant can help control leukemia and lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab attaches to CD22-... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
03/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Recruiting
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Alta Bates Summit Medical Center, Berkeley, California +71 locations
Conditions: Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruiting
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: UC San Diego Moores Cancer Center, La Jolla, California +5 locations
Conditions: Lymphoma
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Recruiting
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's Dementia (AD) and the hematological malignancies leading to HCT. There are shared mechanisms and interactions between AD and cancer-related cognitive decline (CRCD). Physical activity improves cogniti... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/03/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes (MDS)
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Recruiting
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey +6 locations
Conditions: T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma, T-cell Leukemia, Lymphoma
Vaccine Responses in Patients With B Cell Malignancies
Recruiting
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn h... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
Recruiting
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
02/25/2025
Locations: Research Site, Miami, Florida +19 locations
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
Recruiting
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
Gender:
ALL
Ages:
Between 50 years and 99 years
Trial Updated:
02/21/2025
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma +1 locations
Conditions: Breast Cancer, Lymphoma